View in EDS

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.

Saved in:
Bibliographic Details
Title: Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Authors: Coffey GP; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California. gcoffey@portola.com., Feng J; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Betz A; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Pandey A; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Birrell M; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Leeds JM; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Der K; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Kadri S; Department of Pathology, University of Chicago, Chicago, Illinois., Lu P; Department of Pathology, University of Chicago, Chicago, Illinois., Segal J; Department of Pathology, University of Chicago, Chicago, Illinois., Wang YL; Department of Pathology, University of Chicago, Chicago, Illinois., Michelson G; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Curnutte JT; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Conley PB; Biology, Portola Pharmaceuticals, Inc., South San Francisco, California.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Feb 15; Vol. 25 (4), pp. 1174-1184. Date of Electronic Publication: 2018 Oct 17.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30333224
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Coffey+GP%22">Coffey GP</searchLink>; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California. gcoffey@portola.com.<br /><searchLink fieldCode="AU" term="%22Feng+J%22">Feng J</searchLink>; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Betz+A%22">Betz A</searchLink>; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Pandey+A%22">Pandey A</searchLink>; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Birrell+M%22">Birrell M</searchLink>; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Leeds+JM%22">Leeds JM</searchLink>; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Der+K%22">Der K</searchLink>; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Kadri+S%22">Kadri S</searchLink>; Department of Pathology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Lu+P%22">Lu P</searchLink>; Department of Pathology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Segal+J%22">Segal J</searchLink>; Department of Pathology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Wang+YL%22">Wang YL</searchLink>; Department of Pathology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Michelson+G%22">Michelson G</searchLink>; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Curnutte+JT%22">Curnutte JT</searchLink>; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Conley+PB%22">Conley PB</searchLink>; Biology, Portola Pharmaceuticals, Inc., South San Francisco, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2019 Feb 15; Vol. 25 (4), pp. 1174-1184. <i>Date of Electronic Publication: </i>2018 Oct 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30333224
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-18-1047
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1174
    Titles:
      – TitleFull: Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Coffey GP
      – PersonEntity:
          Name:
            NameFull: Feng J
      – PersonEntity:
          Name:
            NameFull: Betz A
      – PersonEntity:
          Name:
            NameFull: Pandey A
      – PersonEntity:
          Name:
            NameFull: Birrell M
      – PersonEntity:
          Name:
            NameFull: Leeds JM
      – PersonEntity:
          Name:
            NameFull: Der K
      – PersonEntity:
          Name:
            NameFull: Kadri S
      – PersonEntity:
          Name:
            NameFull: Lu P
      – PersonEntity:
          Name:
            NameFull: Segal J
      – PersonEntity:
          Name:
            NameFull: Wang YL
      – PersonEntity:
          Name:
            NameFull: Michelson G
      – PersonEntity:
          Name:
            NameFull: Curnutte JT
      – PersonEntity:
          Name:
            NameFull: Conley PB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 02
              Text: 2019 Feb 15
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1